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Objective: The authors conducted a genome-wide associ-
ation study of anorexia nervosa and calculated genetic
correlations with a series of psychiatric, educational, and
metabolic phenotypes.
Method: Following uniform quality control and imputation
procedures using the 1000 Genomes Project (phase 3)
in 12 case-control cohorts comprising 3,495 anorexia
nervosa cases and 10,982 controls, the authors performed
standard association analysis followed by a meta-analysis
across cohorts. Linkage disequilibrium score regression
was used to calculate genome-wide common variant
heritability (single-nucleotide polymorphism [SNP]-based
heritability [h2SNP]), partitioned heritability, and genetic
correlations (rg) between anorexia nervosa and 159 other
phenotypes.
Results: Results were obtained for 10,641,224 SNPs and
insertion-deletion variantswithminor allele frequencies.1%
and imputation quality scores .0.6. The h2SNP of anorexia
nervosa was 0.20 (SE=0.02), suggesting that a substantial
fraction of the twin-based heritability arises from common
genetic variation. The authors identified one genome-wide
significant locus on chromosome 12 (rs4622308) in a region
harboring a previously reported type 1 diabetes and auto-
immune disorder locus. Significant positive genetic cor-
relations were observed between anorexia nervosa and
schizophrenia, neuroticism, educational attainment, and
high-density lipoprotein cholesterol, and significant negative
genetic correlations were observed between anorexia
nervosa and body mass index, insulin, glucose, and lipid
phenotypes.
Conclusions: Anorexia nervosa is a complex heritable phe-
notype for which this study has uncovered the first genome-
wide significant locus. Anorexia nervosa also has large and
significant genetic correlations with both psychiatric phe-
notypes and metabolic traits. The study results encourage a
reconceptualization of this frequently lethal disorder as one
with both psychiatric and metabolic etiology.
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Anorexia nervosa is a serious eating disorder characterized by
restriction of energy intake relative to requirements, resulting
in abnormally low body weight. It has a lifetime prevalence of
approximately 1%anddisproportionately affects females (1, 2),
and no well-replicated evidence of effective pharmacological
or psychological treatments for it have been identified, despite
high morbidity and mortality (3, 4). Twin studies consistently
support a genetic basis for the observed familial aggregation
in anorexia nervosa, with heritability estimates in the range
of 48%–74% (5). Although initial genome-wide association stud-
ies (GWASs) were underpowered (6, 7), the available evidence
strongly suggested that signals for anorexia nervosawould be
detected with increased sample size (6).
Our aim in the present study was to combine existing
samples to conduct a more powerful GWAS of anorexia
nervosa. To further characterize the nature of the illness, we
applied linkage disequilibrium (LD) score regression (8) to
calculate genome-wide common variant heritability (single-
nucleotide polymorphism [SNP]-based heritability [h2SNP]),
partitionedheritability, and genetic correlations (rg) between
anorexia nervosa and other phenotypes. These include the
othermajor psychiatric disorders with large GWASs, namely
schizophrenia, bipolar disorder, major depressive disorder,
autism, and attention deficit hyperactivity disorder (ADHD),
as well as medical, educational, and personality phenotypes.
We then used rg estimates between anorexia nervosa and
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were ,100. After removing these three data sets and com-
bining the U.S. and Canadian cases, we included 11 GCAN/
WTCCC3–based data sets plus the CHOP/PFCG data set in
our analyses. For the nine data sets requiring new controls,
we first evaluated diverse control data sets from Psychiatric
Genomics Consortium collaborators for potentially suitable
controls based on geographic location and Illumina geno-
typing.We thenperformedquality control steps (see below;
additional details are provided in the data supplement),
using visual inspection of principal component plots (com-
paring cases to controls) as well as quantile-quantile (QQ)
and Manhattan plots (for evidence of systematic bias) to
identify suitablymatched controls. All samples in the present
study are of European ancestry. As shown in Figure S1 in the
data supplement, all of the data sets (except the one from
Finland) form a gradient of clusters when visualized in a
scatterplot of thefirst two principal components, as expected
based on known population genetic features (15).
Quality Control and Analysis
After uniform quality control and imputation using the
1000 Genomes Project (phase 3) (16) in the anorexia nervosa
case-control cohorts,weperformedassociationanalysiswithan
additive model using the dosage (the expected count of one of
the alleles) for each genotype for each individual for each co-
hort.Afteradjustment forunbalancedcaseandcontrolnumbers
across our 12 strata (see reference 17), our summed effective
balanced sample size was 5,082 cases and 5,082 controls. Ac-
cordingly, our power was 83.1% for a genotype relative risk of
1.25, at an allele frequency of 0.2 at p,531028 (http://zzz.bwh.
harvard.edu/gpc). Analysis within data sets was performed in
PLINK with the first 10 principal components as covariates.
METAL (17) was used to conduct fixed-effects meta-analysis
across the 12 data sets using inverse-variance weighting.
Results were obtained for 10,641,224 SNPs and insertion-
deletion variants with minor allele frequencies .1% and
imputation quality scores.0.6 (for the QQ plot, see Figure
S2 in the data supplement). The GWAS statistic inflation
factor (l) was 1.080, with a sample-size-adjusted l1000 of
1.008, consistent with minimal population stratification or
other systematic biases. Plotting was performed in R (18)
and with LocusZoom (19). See the data supplement for
additional methods and quality control details, and Table S1
for individual study details.
Statistical Significance
The primary analysis in this study is the GWAS, which an-
alyzes each SNP for association with phenotype. The in-
ternational standard for statistical significance is p,531028,
which corrects for the approximately 1 million independent
statistical tests conducted. Focused secondary analyses are
now the expectation for primary GWAS reports, and we
describe statistical significance thresholds for them in-
dividually. For LD score regression genetic correlations (rg),
we used the false discovery rate. Gene-based and pathway
analyses were also conducted. For these analyses, statistical
159 additional phenotypes to characterize the phenome-wide 
genetic architecture of anorexia nervosa.
METHOD
Cases and Controls
Our sample included 3,495 anorexia nervosa cases and 10,982 
controls. Case definition required a lifetime diagnosis of 
anorexia nervosa (restricting or binge-purge subtype) or 
lifetime eating disorder not otherwise specified, anorexia 
nervosa subtype (i.e., exhibiting the core features of anorexia 
nervosa). A lifetime history of bulimia nervosa was allowed, 
given the frequency of diagnostic crossover (9). Amenorrhea 
was not required, because it does not increase diagnostic 
specificity (10) (and it was removed as a diagnostic criterion 
in DSM-5 [11]). Extensive information on diagnostic and 
consensus procedures for the samples included in the Child-
ren’s Hospital of Philadelphia/Price Foundation Collabo-
rative Group (CHOP/PFCG) cohort is available elsewhere 
(7). The cases included from the Genetic Consortium for 
Anorexia Nervosa/Wellcome Trust Case Control Consortium–3 
(GCAN/WTCCC3) GWAS came from 12 previously collected 
clinical or population cohorts. Given that these were archived 
samples, the calculation of reliability statistics on diagnoses was 
not possible. Mitigating that concern, however, is that anorexia 
nervosa is a highly homogeneous phenotype with high inter-
rater agreement  for diagnosis  (typical kappa values range from 
0.81 to 0.97 [12]). Moreover, the approach taken here is consis-
tent with successful GWAS meta-analysis efforts across psychia-
tric diagnoses, in which larger samples are used to detect the 
modest effects of typical single common genetic risk variants.
Individuals with schizophrenia, intellectual disability, 
and medical or neurological conditions causing weight loss 
were excluded, as in previous studies (6, 7). All sites had 
documented permission from local ethical committees, and 
all participants provided informed consent.
Consistent with procedures established by the Psychiatric 
Genomics Consortium (13, 14), we collected individual-level 
genotype (GWAS array) and phenotype (binary case-control 
status) data from contributing previous GWAS consortia and 
groups (for a description, see Table S1 in the data supple-
ment that accompanies the online edition of this article). In 
particular, the previous reports on anorexia nervosa GWASs 
from CHOP/PFCG data (7) and the GCAN/WTCCC3 (6) provide 
further details about cohort ascertainment and participant char-
acteristics not described below or in the online data supplement.
Although most of the cases included in the published 
anorexia nervosa GWASs were included in this analysis, 
many of the controls used in previous GWASs could not be 
used for subsequent analyses. To summarize, our analysis 
includes the CHOP/PFCG data (7) plus cases from 12 of the 
15 strata included in the GCAN/WTCCC3 analysis of an-
orexia nervosa. Three data sets (Italy-North, Sweden, and 
Poland) from the Boraska et al. study (6) were dropped from 
our analysis either because appropriately matched controls 
could not be found or because case plus control numbers
anorexia nervosa and compare it with other complex dis-
orders and traits, within and outside psychiatry.
RESULTS
GWAS
One locus achieved genome-wide significance for a single
variant, as shown in theManhattan plot in Figure 1, in which
the threshold for significance (p,531028) is denoted with
a dotted line. The top locus (chromosome 12q13.2) over-
laps six genes (IKZF4, RPS26, ERBB3, PA2G4, RPL41, and
ZC3H10) and is located near six additional genes (ESYT1,
SUOX, RAB5B, CDK2, PMEL, and DGKA). The top SNP was
rs4622308 (p=4.331029, odds ratio=1.2, SE=0.03; minor
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a In panel A, a Manhattan plot depicts a genome-wide significant locus on chromosome 12. The threshold for significance (see dotted horizontal line)
is 7.3, which is –log10(5310
28). In panel B, a regional plot of the top locus reveals numerous genes in the region. Results depicted here reflect
the full meta-analysis. See Figure S5 in the online data supplement for regional plot with phenotypic associations.
significance was set using the Bonferroni correction, which 
is conservative given nonindependence among the gene-
based and pathway statistical tests. For the gene-based 
analyses, we defined statistical significance as a gene p value 
,2.631026 (0.05/19,222 genes tested), and for pathway an-
alyses, a p value ,1.831025 (0.05/2,714 pathways tested).
Analytical methods for estimating heritability and genetic 
correlations and for gene-based and pathway analyses are 
presented in the data supplement. Regarding the rationale for 
these particular secondary analyses, we note that these are 
often considered to be standard analyses for GWAS reports 
across medicine. In this particular application, we estimate 
SNP heritability for anorexia nervosa because it is important 
to quantify the combined effects of common variants on
FIGURE 1. Manhattan Plot and Regional Plot of the Genome-Wide Significant Locus for Anorexia Nervosaa 
A
Linkage Disequilibrium Score Regression
LD score regression (8, 23) was used to calculate h2SNP,
partitioned heritability, and rg between anorexia nervosa and
other psychiatric, medical, educational, and personality
phenotypes.
In our cohort, h2SNP for anorexia nervosa was 0.20
(SE=0.021), comparable to h2SNP estimates for other psy-
chiatric disorders (see Figure S8 in the data supplement).
Partitioned heritability estimates for annotation categories
and cell types were not significant after correction for mul-
tiple testing (for complete results, see Table S4 in the data
supplement).
A wide range of both positive and negative genetic
correlations between anorexia nervosa and other phe-
notypes were statistically significant. Of 159 phenotypes
tested, 29 had a false discovery rate ,0.05 (uncorrected
p values reported below). See Figure 2 for a depiction of
these genetic correlations, and the text below for se-
lected examples. All 159 genetic correlations and rele-
vant references are available in Table S5 in the data
supplement.
Notable significant genetic correlations between an-
orexia nervosa and psychiatric traits and disorders were
neuroticism (rg=0.39, SE=0.14, p=4.4310
23), schizophrenia
(rg=0.29, SE=0.07, p=4.4310
25), and results from a meta-
analysis across psychiatric phenotypes (rg=0.22, SE=0.07,
p=3.431023). Genetic correlations between anorexia ner-
vosa and the educational phenotypes of years of education
(rg=0.34, SE=0.08, p=5.2310
26) and attending college
(rg=0.30, SE=0.07, p=4.4310
25) were also positive and sig-
nificant. Obsessive-compulsive disorder (OCD) GWAS data
were unavailable to us, but a previous analysis (24) reported
a positive rg with anorexia nervosa of 0.53 (SE=0.12,
p=5.531026).
Several significant negative genetic correlations emerged
between anorexia nervosa and weight-related phenotypes,
suggesting shared genetic loci underlying these phenotypes
and opposing effects for relevant alleles. Extreme high body
mass index (BMI) was significantly negatively correlated
with anorexia nervosa (rg=20.29, SE=0.08, p=2.0310
24)
as were obesity, BMI in the normal range, overweight,
and hip circumference, with genetic correlations ranging
from 20.2 to 20.3.
We also observed significant negative genetic correlations
between anorexia nervosa and insulin- and glucose-related
traits: insulin resistance (HOMA-IR) (rg=20.50, SE=0.11,
p=1.33 1025) and fasting insulin (rg=20.41, SE=0.09,
p=5.231026) were the largest-magnitude genetic correlations
observed, aside from the previous report of OCD (24). A
negative genetic correlation with fasting glucose (rg=20.26,
SE=0.07, p=3.031024) was also observed. Although genome-
wide BMI-corrected HOMA-IR GWAS statistics were not
available, we observed a negative rg of BMI-corrected GWAS
results for the closely related trait of leptin levels (rg=20.24,
SE=0.11, p=0.03), which suggests a role for BMI-independent
glucose-related metabolism in anorexia nervosa. Regarding
allele frequency in cases [MAFcases]=0.48, minor allele fre-
quency in controls [MAFcontrols]=0.44). We found no evi-
dence for heterogeneity in effect sizes across cohorts 
(Q=12.58, p=0.32), and we estimated that 12.59% of the var-
iation was due to heterogeneity rather than chance (I2=12.59). 
The effects across studies are shown in the forest plot of 
rs4622308 in Figure S3 in the data supplement.
The results of conditional regression analyses are con-
sistent with the existence of one signal at the top locus (see 
Figure S4 in the data supplement). The top SNP, rs4622308, 
is in high LD (r2=0.86; D:.0.99) with rs11171739, which 
was found to be associated with type 1 diabetes (20) and 
rheumatoid arthritis (21) in previous GWASs. The risk-
associated alleles of both SNPs are typically found on the 
same haplotype (C-C); that is, the direction of effect for 
the risk allele is consistent across anorexia nervosa and 
these other two disorders. Several other immune-related 
phenotypes—vitiligo, alopecia areata, and asthma (see 
Figure S5 in the data supplement)—also have associations in 
the region, although these are somewhat LD independent 
of rs4622308.
Information for the top six loci is provided in Table S2 in 
the data supplement. The second (rs200312312 on chromo-
some 5, p=6.731028), third (rs117957029 on chromosome 12, 
p=1.631027), and fourth (rs11174202 on chromosome 12, 
p=3.131027) most significant loci in our analyses also have 
consistent evidence for association across multiple cohorts 
(see Figure S6 in the data supplement for area plots of these 
loci). The fourth best locus is intronic in the FAM19A2 gene. 
Summary statistics are available at https://www.med.unc. 
edu/pgc.
Gene-Based and Pathway Analyses
Multiple genes, all but one of which were in the region around 
the top SNP (rs4622308), reached gene-based significance 
(reflecting the high LD in the region). The remaining sig-
nificant gene was FAM19A2, a putative chemokine/cytokine 
and the fourth best locus in our SNP-based analyses. No 
pathways were significant (see Table S3 in the data supple-
ment for the complete gene-based and pathway analysis 
results). As has typically been reported for other psychiatric 
disorders, candidate genes from previous studies did not 
reach gene-based significance; for a detailed review of the 
candidate gene literature, see reference 5).
Gene Expression
Interrogation of databases such as GTEx (22) did not in-
dicate that any of  the genes  in  the top  region  have distinct  
patterns of brain gene expression. Searches using both 
GTEx and the SNP tag lookup function in MR-Base (www.  
mrbase.org/beta) indicated that the top SNP (rs4622308) is 
not, directly or via LD tagging, an expression or methyl-
ation quantitative trait locus. In addition, differential ex-
pression in an exploratory mouse model did not suggest a 






To our knowledge, this is the
first report of a genome-wide
significant association for
anorexia nervosa. As is typi-
cal of many GWAS loci for
complex disorders, the re-
gion has a common top var-
iant (MAFcontrols=0.44) that
shows a modest odds ratio of
1.2 and implicates a broad
region encompassing multi-
ple genes (25). Consistent
with other GWAS (26), our
genome-wideh2SNPestimate
of 20% for anorexia nervosa
supports a substantial role
for commongenetic variation,
which accounts for a sizable
portion of twin-based heri-
tability (h2Twin=48%–74%)
(6). Furthermore, these re-
sults fit with the expectation
that h2Twin should exceed
h2SNP, because the former
captures the effects of all
types of genetic variation
(common and rare, as well as
variation not captured with
current methods).
The observed pattern of
genetic correlations with
psychiatric, personality, edu-
cational, and metabolic phe-
notypes provides grounds for
broadening our conceptuali-
zation of the disorder. First,
the strong positive genetic correlations of anorexia nervosa
with OCD and neuroticism reinforce clinical and epide-
miological observations. Anorexia nervosa is commonly
comorbid with OCD, and twin studies have reported high
twin-based genetic correlations (27). High neuroticism in
adolescence predicts subsequent onset of anorexia nervosa
(1). In addition, anorexianervosa is commonly comorbidwith
multiple anxiety phenotypes, which often predate the onset
of anorexia nervosa (28).
Second, the positive genetic correlations seen with
schizophrenia and the cross–psychiatric disorder phenotype
firmly anchor anorexia nervosa with other psychiatric dis-
orders and reflect the substantial evidence for partially
shared genetic risk across many psychiatric disorders (29).
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a The 24 correlations depicted here (of 159 phenotypes tested) have a false discovery rate ,0.05. Error
bars indicate standard error. BMI=body mass index; GIANT=Genetic Investigation of Anthropometric
Traits; GPC=Genetics of Personality Consortium; HDL=high-density lipoprotein cholesterol; HOMA-
Beta=homeostatic model assessment of beta cell function; HOMA-IR=homeostatic model assessment
of insulin resistance; PGC=Psychiatric Genomics Consortium; SSGAC=Social Science Genetic Asso-
ciation Consortium.
cholesterol and lipid measures, a distinction between differ-
ent lipid fractions emerges when comparing high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and 
very-low-density lipoprotein (VLDL) phenotypes. Genetic 
correlations between anorexia nervosa and HDL phenotypes 
were positive—for example, total cholesterol in large HDL 
particles (rg=0.39, SE=0.12, p=1.631023), free cholesterol 
in large HDL particles (rg=0.37, SE=0.12, p=2.231023), 
and  phospholipids  in  large  HDL  particles  (rg=0.30, 
SE=0.11, p=6.731023). In contrast, VLDL and LDL cho-
lesterol phenotypes were negatively correlated with an-
orexia nervosa, albeit with nominal significance (i.e., 
uncorrected p,0.05)—for example, total lipids in VLDL 
(rg=20.30, SE=0.12, p=0.01), phospholipids in VLDL (rg=20.33,
FIGURE 2. Genetic Correlations Between Anorexia Nervosa and Diverse Phenotypes Reveal Overlap 
Across Psychiatric, Educational, Weight, Insulin, Lipoprotein, and Cholesterol Phenotypesa
previously reported (23), and our LD score regression
estimate—though only nominally significant—is in the
negative direction as well (see Table S5 in the data
supplement).
Theprimary strengthof this investigation is that it extends
previous work by increasing sample size through collabo-
ration. Nevertheless, contemporary understanding of com-
plex trait genetics suggests that even larger samples are
needed. Since our collection represents all of the currently
GWAS-genotyped anorexia nervosa samples in the world, no
known genotyped replication samples exist. We therefore
expect this to be the beginning of genomic discovery in
eating disorders (25). Future work with additional and
better-powered anorexia nervosa GWASs will clarify the
magnitude of genetic relationships among metabolic and
psychiatric phenotypes, andmethods such as that proposed
by Pickrell et al. (40) will provide clues about the direction
of causal relationships.
In summary, we identified the first robust genome-wide
significant locus for anorexia nervosa, which is also a
previously reported type 1 diabetes and general autoimmune
disorder locus. Perhaps of greater importance is that we
find anorexia nervosa to be a complex heritable phenotype
with intriguingly large and significant genetic correlations
not only with psychiatric disorders but also with multiple
metabolic traits. This encourages a reconceptualization of
this frequently lethal disorder as both psychiatric and met-
abolic. Just as obesity is increasingly considered to be both a
metabolic/endocrine and psychiatric disorder, approaching
anorexia nervosa as both a psychiatric and metabolic con-
dition could ignite interest in developing or repositioning
pharmacological agents for its treatment.
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Third, congruent with our results, positive associations be-
tween anorexia nervosa and educational attainment have 
been reported (30) and have been conjectured to reflect 
greater internal and external demands for academic success 
in highly educated families. Our results, in contrast, suggest 
that genetic factors may partially account for these reported 
associations.
Fourth, the identification of significant negative corre-
lations between anorexia nervosa and BMI-related and 
anthropometric measures could potentially serve as an 
important first step toward gaining a better understanding 
of the shared biology underlying extremes of weight dysreg-
ulation (i.e., obesity versus anorexia nervosa). This is of critical 
importance because adequate explanations for how indi-
viduals with anorexia nervosa reach, sustain, and revert to 
exceedingly low BMIs have been elusive. Clinically, one of the 
most perplexing features of anorexia nervosa is how patients’ 
bodies seem to revert rapidly to a “low set point” after 
renourishment, which may represent the biological inverse 
of the reversion to high set points commonly seen in the 
unsuccessful treatment of obesity (31, 32). As noted by Bulik-
Sullivan et al. (23) and Hinney et al. (33), these observations 
extend our understanding that the same genetic factors that 
influence normal variation in BMI, body shape, and body 
composition may also influence extreme dysregulation of 
these weight-related features in anorexia nervosa. This pat-
tern of observations complements prior strong evidence 
for the involvement of neural mechanisms in obesity (34). 
Finally, positive correlations with “favorable” metabolic 
phenotypes (i.e., HDL and lipid measures) and negative 
correlations with “unfavorable” metabolic phenotypes (i.e., 
fasting insulin level, fasting glucose level, HOMA-IR) en-
courage additional exploration of the role metabolic factors 
may play in extreme dysregulation of appetite and weight in 
anorexia nervosa.
The genome-wide significant locus we identify to be as-
sociated with anorexia nervosa is broad and multigenic 
(chr12:56,372,585–56,482,185). Mechanistic explanations 
about the role of the associated variant require additional 
functional data; nevertheless, we note the possible role for 
genes at this locus in the pathophysiology of anorexia 
nervosa. PA2G4 is involved in growth regulation and acts as a 
co-repressor of the androgen receptor (35). ESYT1 (extended 
synaptotagmin-1, which binds and transports lipids [36]) is 
enriched in the postsynaptic density, which is implicated in 
the etiology of schizophrenia (37). Perhaps more convincing 
is that the sentinel marker for this locus, rs4622308, is in 
high LD with a known GWAS hit for type 1 diabetes (20) and 
rheumatoid arthritis (21), and the region around it harbors 
multiple other autoimmune associations. Multiple reports 
of shared effects between anorexia nervosa and immune 
phenotypes fit into a broader pattern of above-chance 
comorbidity across psychiatric and immune phenotypes 
(38, 39). Evidence suggests that this shared risk is at least 
partly genetic in origin (23, 39). A negative genetic correlation 
between anorexia nervosa and rheumatoid arthritis was
Funding for this project was provided to 56 investigators contributing to
this report as follows: LaramieDuncan: NIMH5U01MH094432-04, NIMH
3U01MH094432-03S1; Stephan Ripke: NIMH MH109528, NARSAD
23545; Mark Daly: NIMH MH109528; Youl-Ri Kim: Research of Korea
Centers for Disease Control and Prevention Fund (code HD16A1351);
Susana Jiménez-Murcia: Instituto de Salud Carlos III (FIS PI14/290 and
CIBERobn); Fernando Fernández-Aranda: Instituto de Salud Carlos III (FIS
PI14/290 and CIBERobn); Philip Gorwood: EC Framework V “Factors in
Healthy Eating” from INRA/INSERM (4M406D), PHRC ENDANO (2008-
A01636-49); Paolo Santonastaso (for PAUDA Group): Veneto Region
Grant BIOVEDA, contract grant number DGR 3984/08; Leila Karhunen:
Academy of Finland (28327); Anu Raevuori: Academy of Finland grant
number 259764; André Scherag: Federal Ministry of Education and Re-
search, Germany, FKZ 01EO1502; Andrew Bergen: Professional Services
Agreement with the Regents of the University of California; Stephanie
Le Hellard: Bergen Research Foundation, NFR (NORMENT-SFF), K.G.
Jebsen Foundation, Norwegian Cognitive NeuroGenetics, the University
of Bergen, Dr. Einar Martens Fund, the Research Council of Norway,
to Stephanie Le Hellard, Vidar Steen, and Thomas Espeseth; Hakon
Hakonarson: Institutional Development Fund to the Center for Applied
Genomics from Children’s Hospital of Philadelphia, Electronic Medical
Records and Genomics (eMERGE) Network (U01 HG006830) from the
NationalHumanGenomeResearch Institute,NIH,Kurbert Family;DongLi:
Davis Foundation Postdoctoral Fellowship Program in Eating Disorders
Research Award; Yiran Guo: Davis Foundation Postdoctoral Fellowship
Program in Eating Disorders Research Award; Shuyang Yao: China
Scholarship Council; Sietske Helder: European Commission (2008–2011)
Early Stage Researcher from the Research Training Network INTACT
(Individually Tailored Stepped Care for Women with Eating Disorders) in
theMarie Curie Program (MRTN-CT-2006-035988); Stephen Scherer:
Genome Canada, the government of Ontario, the Canadian Institutes
of Health Research, University of Toronto McLaughlin Centre; Martina de
Zwaan: FederalMinistry for Education andResearch,Germany, 01GV0601
and 01GV0624; Anke Hinney: Ministry for Education and Research,
Germany (National Genome Research Net-Plus 01GS0820) and the
German Research Foundation (HI865/2-1); Tracey Wade: Grants
324715 and 480420 from the National Health and Medical Research
Council (NHMRC), Australian Twin Registry supported by Enabling Grant
(ID 310667) from the NHMRC (University of Melbourne); Hana Papezova:
Internal Grant Agency of the Ministry of Health of the Czech Republic
IGA MZ CR NT 14094-3/2013; Karen Mitchell: K01MH093750; Jessica
Baker: K01MH106675; Zeynep Yilmaz: K01MH109782; Danielle Dick:
K02AA018755-06, R01AA015416-08, National Institute on Alcohol Abuse
and Alcoholism; Mikael Landén: Klarman Family Foundation; Sarah
Cohen-Woods: Matthew Flinders Fellowship, Flinders University, Australia;
Matthias Tschöp: Alexander von Humboldt Foundation, Helmholtz
Alliance ICEMED-Imaging and Curing Environmental Metabolic Diseases
through the InitiativeandNetworkingFundof theHelmholtzAssociation,
the Helmholtz cross-program topic “Metabolic Dysfunction,” German
Research Foundation (DFG-TS226/1-1 and TS226/3-1, European Re-
searchCouncilConsolidatorGrant (HepatpMetaboPath); BeateHerpertz-
Dahlmann:Ministry for Research andEducation, Germany;Nicole Soranzo:
Wellcome Trust (grant codes WT098051 and WT091310), EU FP7
(EPIGENESYS grant code 257082 and BLUEPRINT grant code HEALTH-
F5-2011-282510), National Institute for Health Research Blood and
Transplant Research Unit in Donor Health and Genomics at the University
of Cambridge in partnershipwithNHSBlood andTransplant; Allan Kaplan:
Ontario Mental Health Foundation, Ministry of Health of Ontario AFP
Innovation Fund; Wade Berrettini: Price Foundation; Marion Roberts:
Psychiatry ResearchTrust (registered charity no. 284286); Patrick Sullivan:
R01 MH109528, D0886501, Swedish Research Council; Thomas
Espeseth: Research Council of Norway, and South-East Norway Regional
Health Authority; Michael Strober: Resnick Family Chair in Eating Disor-
ders; Xavier Estivill: SpanishMinistry of Economy andCompetitiveness no.
SAF2013-49108-R, the Generalitat de Catalunya AGAUR 2014 SGR-1138,
the European Commission Seventh Framework Program (FP7/2007-
2013) 262055 (ESGI); Lenka Foretova: MH CZ-DRO (MMCI, 00209805);
Crawford, M.D., Scott Crow, M.D., Jim Crowley, Ph.D., Unna Danner, Ph.D., 
Oliver Davis, M.Sc., Ph.D., Martina de Zwaan, M.D., George Dedoussis, 
Ph.D., Daniela Degortes, Ph.D., Janiece DeSocio, Ph.D., R.N., Danielle 
Dick, Ph.D., Dimitris Dikeos, M.D., Christian Dina, Ph.D., Bo Ding, Ph.D., 
Monika Dmitrzak-Weglarz, Ph.D., Elisa Docampo, M.D., Ph.D., Karin 
Egberts, M.D., Stefan Ehrlich, M.D., Geòrgia Escaramís, Ph.D., Tõnu Esko, 
Ph.D., Thomas Espeseth, Ph.D., Xavier Estivill, M.D., Ph.D., Angela Favaro, 
M.D., Ph.D., Fernando Fernández-Aranda, Ph.D., F.A.E.D., Manfred Fichter, 
M.D., Dipl.-Psych., Chris Finan, Ph.D., Krista Fischer, Ph.D., James Floyd, 
Ph.D., Manuel Föcker, M.D., Lenka Foretova, M.D., Ph.D., Monica Forzan, 
Ph.D., Caroline Fox, M.D., Christopher Franklin, Ph.D., Valerie Gaborieau, 
Steven Gallinger, M.D., Giovanni Gambaro, M.D., Ph.D., Ina Giegling, Ph.D., 
Fragiskos Gonidakis, M.D., Philip Gorwood, M.D., Ph.D., Monica Gratacos, 
M.D., Ph.D., Sébastien Guillaume, M.D., Ph.D., Yiran Guo, Ph.D., Hakon 
Hakonarson, M.D., Ph.D., Katherine Halmi, M.D., Rebecca Harrison, 
Konstantinos Hatzikotoulas, M.D., Ph.D., Joanna Hauser, M.D., Ph.D., 
Johannes Hebebrand, M.D., Sietske Helder, Ph.D., Judith Hendriks, B.Sc., 
Stefan Herms, Ph.D., Beate Herpertz-Dahlmann, M.D., Wolfgang Herzog, 
M.D., Christopher Hilliard, B.S., Laura Huckins, Ph.D., James Hudson, M.D., 
Sc.D., Julia Huemer, M.D., Hartmut Imgart, M.D., Hidetoshi Inoko, Ph.D., 
Sigrid Jall, Stephane Jamain, Ph.D., Vladimir Janout, Ph.D., Susana 
Jiménez-Murcia, Ph.D., Craig Johnson, Ph.D., Jenny Jordan, Ph.D., 
Antonio Julià, Ph.D., Anders Juréus, Ph.D., Gursharan Kalsi, Ph.D., Allan 
Kaplan, M.D., F.R.C.P.(C.), Jaakko Kaprio, M.D., Ph.D., Leila Karhunen, 
Ph.D., Andreas Karwautz, M.D., F.A.E.D., Martien Kas, Ph.D., Walter Kaye, 
M.D., Martin Kennedy, Ph.D., James Kennedy, M.D., F.R.C.P.(C.), Anna 
Keski-Rahkonen, M.D., Ph.D., Kirsty Kiezebrink, Ph.D., F.H.E.A., Youl-Ri 
Kim, M.D., Ph.D., Lars Klareskog, M.D., Kelly Klump, Ph.D., Gun Peggy 
Knudsen, Ph.D., Bobby Koeleman, Ph.D., Doris Koubek, M.D., Maria La Via, 
M.D., Mikael Landén, M.D., Ph.D., Stephanie Le Hellard, Ph.D., Marion 
Leboyer, M.D., Ph.D., Robert Levitan, M.D., Dong Li, Ph.D., Paul Lichtenstein, 
Ph.D., Lisa Lilenfeld, Ph.D., Jolanta Lissowska, Ph.D., Astri Lundervold, 
Ph.D., Pierre Magistretti, Ph.D., Mario Maj, M.D., Ph.D., Katrin Mannik, 
Ph.D., Sara Marsal, M.D., Ph.D., Debora Kaminska, Ph.D., Nicholas 
Martin, Ph.D., Morten Mattingsdal, Ph.D., Sara McDevitt, M.D.,  M.R.C.  
Psych., Peter McGuffin, M.D., Elisabeth Merl, M.D., Andres Metspalu, 
Ph.D., M.D., Ingrid Meulenbelt, Ph.D., Nadia Micali, M.D., Ph.D., James 
Mitchell, M.D., Karen Mitchell, Ph.D., Palmiero Monteleone, M.D., 
Alessio Maria Monteleone, M.D., Grant Montgomery, Ph.D., Preben 
Mortensen, M.D., Dr.Med.Sc., Melissa Munn-Chernoff, Ph.D., Timo 
Müller, Ph.D., Benedetta Nacmias, Ph.D., Marie Navratilova, M.U.Dr., 
Ph.D., Ida Nilsson, Ph.D., Claes Norring, Ph.D., Ioanna Ntalla, Ph.D., 
Roel Ophoff, Ph.D., Julie O’Toole, M.D., Aarno Palotie, M.D., Ph.D., 
Jacques Pantel, Ph.D., Hana Papezova, M.D., Ph.D., Richard Parker, 
Dalila Pinto, Ph.D., Raquel Rabionet, Ph.D., Anu Raevuori, M.D., Ph.D., 
Andrzej Rajewski, M.D., Ph.D., Nicolas Ramoz, Ph.D., N. William Rayner, 
Ph.D., Ted Reichborn-Kjennerud, M.D., Valdo Ricca, M.D., Samuli 
Ripatti, Ph.D., Franziska Ritschel, M.Sc., Marion Roberts, Ph.D., Alessandro 
Rotondo, M.D., Dan Rujescu, M.D., Filip Rybakowski, M.D., Ph.D., Paolo 
Santonastaso, M.D., André Scherag, Ph.D., Stephen Scherer, Ph.D., F.R.S.C., 
Ulrike Schmidt, M.D., Ph.D., Nicholas Schork, Ph.D., Alexandra Schosser, 
Ph.D., Laura Scott, Ph.D., Jochen Seitz, M.D., Lenka Slachtova, Ph.D., Robert 
Sladek, M.D., P. Eline Slagboom, Ph.D., Margarita Slof-Op ’t Landt, Ph.D., 
Agnieszka Slopien, M.D., Tosha Smith, Ph.D., Nicole Soranzo, Ph.D., Sandro 
Sorbi, M.D., Lorraine Southam, B.Sc., Vidar Steen, M.D., Ph.D., Eric 
Strengman, B.S., Michael Strober, Ph.D., Jin Szatkiewicz, Ph.D., Neonila 
Szeszenia-Dabrowska, M.D., Ph.D., Ioanna Tachmazidou, Ph.D., Elena  
Tenconi, M.D., Alfonso Tortorella, M.D., Federica Tozzi, M.D., Janet 
Treasure, Ph.D., F.R.C.P., Matthias Tschöp, M.D., Artemis Tsitsika, M.D., 
Ph.D., Konstantinos Tziouvas, M.D., M.Sc., Annemarie van Elburg, M.D., 
Ph.D., Eric van Furth, Ph.D., Tracey Wade, Ph.D., Gudrun Wagner, D.O., 
D.P.O., Esther Walton, Dr.rer.nat., Ph.D., Hunna Watson, Ph.D., H-Erich 
Wichmann, Ph.D., Elisabeth Widen, M.D., Ph.D., D. Blake Woodside, M.D., 
Jack Yanovski, M.D., Ph.D., Shuyang Yao, M.Sc., Stephanie Zerwas, Ph.D., 
Stephan Zipfel, M.D., Laura Thornton, Ph.D., Anke Hinney, Ph.D., Mark 
Daly, Ph.D., Patrick F. Sullivan, M.D., F.R.A.N.Z.C.P., Eleftheria Zeggini, 
Ph.D., Gerome Breen, Ph.D., Cynthia M. Bulik, Ph.D.
GlaxoSmithKline, Janssen, Lundbeck, Organon, Sanofi, UniPharma, and
Wyeth, and he has received unrestricted grants from Eli Lilly and AstraZeneca
as director of the Sleep Research Unit of Eginition Hospital (National and
Kapodistrian University of Athens, Greece). Dr. Kaplan has served on the Shire
Canada BED advisory board. Dr. Kennedy is an unpaid member of the
scientific advisory board of AssurexHealth. Dr. Landén has received
lecture honoraria fromAstraZeneca, Biophausia Sweden, and Lundbeck
and has served as a scientific consultant for EPID Research Oy. Dr.
Treasure has received a speaking honorarium from Eli Lilly and royalties
for a published book.
ReceivedDec. 17, 2016; revision receivedFeb.26,2017; acceptedMarch9,
2017; published online May 12, 2017.
REFERENCES
1. Bulik C, Sullivan P, Tozzi F, et al: Prevalence, heritability, and
prospective risk factors for anorexia nervosa. Arch Gen Psychiatry
2006; 63:305–312
2. HudsonJI,HiripiE,PopeHGJr, et al: Theprevalence andcorrelates
of eating disorders in the National Comorbidity Survey Replication.
Biol Psychiatry 2007; 61:348–358
3. WatsonHJ, Bulik CM:Update on the treatment of anorexia nervosa:
review of clinical trials, practice guidelines, and emerging inter-
ventions. Psychol Med 2013; 43:2477–2500
4. SteinhausenH, JakobsenH,HeleniusD, et al: Anation-wide studyof
the familyaggregationandrisk factors in anorexianervosaover three
generations. Int J Eat Disord 2015; 48:1–8
5. Yilmaz Z, Hardaway JA, Bulik CM: Genetics and epigenetics of
eating disorders. Adv Genom Genet 2015; 5:131–150
6. Boraska V, Franklin CS, Floyd JA, et al: A genome-wide association
study of anorexia nervosa. Mol Psychiatry 2014; 19:1085–1094
7. Wang K, Zhang H, Bloss CS, et al: A genome-wide association study
on common SNPs and rare CNVs in anorexia nervosa. Mol Psy-
chiatry 2011; 16:949–959
8. Bulik-Sullivan BK, Loh PR, Finucane HK, et al: LD score regression
distinguishes confounding from polygenicity in genome-wide as-
sociation studies. Nat Genet 2015; 47:291–295
9. Tozzi F, Thornton L, Klump K, et al: Symptom fluctuation in eating
disorders: correlates of diagnostic crossover. Am J Psychiatry 2005;
162:732–740
10. Pinheiro A, Thornton L, Plotonicov K, et al: Patterns of menstrual
disturbance in eating disorders. Int J Eat Disord 2007; 40:424–434
11. AmericanPsychiatricAssociation:Diagnostic andStatisticalManual
ofMental Disorders, 5th ed.Washington, DC, American Psychiatric
Association, 2013
12. Sysko R, Roberto CA, Barnes RD, et al: Test-retest reliability of the
proposed DSM-5 eating disorder diagnostic criteria. Psychiatry Res
2012; 196:302–308
13. Psychiatric GWAS Consortium Steering Committee: A framework
for interpreting genome-wide association studies of psychiatric
disorders. Mol Psychiatry 2009; 14:10–17
14. Schizophrenia Working Group of the Psychiatric Genomics
Consortium: Biological insights from 108 schizophrenia-associated
genetic loci. Nature 2014; 511:421–427
15. Novembre J, Johnson T, Bryc K, et al: Genes mirror geography
within Europe. Nature 2008; 456:98–101
16. Clarke L, Fairley S, Zheng-Bradley X, et al: The International Ge-
nome Sample Resource (IGSR): a worldwide collection of genome
variation incorporating the 1000 Genomes Project data. Nucleic
Acids Res 2016; 45(D1):D854–D859
17. WillerC,LiY,AbecasisG:METAL: fast andefficientmeta-analysisof
genomewide association scans. Bioinformatics 2010; 26:2190–2191
18. Ihaka R, GentlemanRR: A language for data analysis and graphics. J
Comput Graph Stat 1996; 5:299–314
19. Pruim RJ, Welch RP, Sanna S, et al: LocusZoom: regional visuali-
zationof genome-wideassociation scanresults.Bioinformatics 2010;
26:2336–2337
Ole Andreassen: Research Council of Norway (248778, 223273), KG 
Jebsen Foundation; Timo Müller: Helmholtz Alliance ICEMED–Imaging 
and Curing Environmental Metabolic Diseases through the Initiative and 
Networking Fund of the Helmholtz Association, Helmholtz cross-
program topic “Metabolic Dysfunction,” German Research Foundation 
(DFG-TS226/1-1 and TS226/3-1); Cynthia Bulik: the Klarman Family 
Foundation, Wellcome Trust WT088827/Z/09, Swedish Research Council 
(VR Dnr: 538-2013-8864); Preben Mortensen: the Klarman Family 
Foundation, unrestricted grant from the Lundbeck Foundation, iPSYCH 
(Initiative for Integrative Psychiatric Research), Aarhus University for 
CIRRAU (Centre of Integrated Register-Based Research); Walter Kaye: the 
Price Foundation, NIMH R01 MH092793; Ted Reichborn-Kjennerud: 
Norwegian Research Council, Norwegian Foundation for Health and 
Rehabilitation; Eleftheria Zeggini: the Wellcome Trust (WT098051); 
Martien Kas: ZonMW VIDI Grant (91786327) from the Netherlands Or-
ganization for Scientific Research (NWO); Tonu Esko: EU H2020 grants 
692145, 676550, 654248, Estonian Research Council Grant IUT20-60, 
NIASC, EIT–Health and NIH-BMI grant 2R01DK075787-06A1, and the 
European Union through the European Regional Development Fund 
(project no. 2014-2020.4.01.15-0012 GENTRANSMED; Stefan Ehrlich: 
German Research Foundation (EH 367/5-1 and SFB 940), Swiss Anorexia 
Nervosa Foundation; Esther Walton: German Research Foundation (EH 
367/5-1 and SFB 940), Swiss Anorexia Nervosa Foundation; Ulrike 
Schmidt: National Institutes of Health Research Mental Health Biomedical 
Research Centre at South London and Maudsley National Health Service 
Foundation Trust and King’s College London; Martin Kennedy: University 
of Otago Research Grant; Johannes Hebebrand: German Ministry for 
Education and Research (National Genome Research Net-Plus 01GS0820 
and 01KU0903), German Research Foundation (DFG; HI865/2-1), Euro-
pean Community’s Seventh Framework Program (FP7/2007-2013) under 
grant agreement no. 245009 and no. 262055; Stephan Zipfel: German 
Ministry for Education and Research (ANTOP-study project, no. 
01GV0624); Gerome Breen: the UK Medical Research Council (G0901245), 
the National Institute for Health Research Biomedical Research Centre 
at South London and Maudsley NHS Foundation Trust, and King’s 
College London, as well as support from NIMH (U01MH109528).
The authors thank the study participants, the study coordinators, vol-
unteers, and research staff who enabled this work, the Wellcome Trust, the 
Price Family Collaborative Group, NIMH, and the computational in-
frastructure provided by the Psychiatric Genomics Consortium. The 
authors from the Children’s Hospital of Philadelphia/Price Foundation 
Collaborative Group thank the Price Foundation for their support in 
recruiting patients, collecting clinical information, and providing DNA 
samples used in this study; the Klarman Family Foundation for supporting 
the study; the technical staff at the Center for Applied Genomics at 
Children’s Hospital of Philadelphia for generating genotypes used for 
analyses; and the nursing, medical assistant, and medical staff for their 
invaluable assistance with sample collection. Data on glycemic traits were 
contributed by the investigators from the Meta-Analyses of Glucose and 
Insulin-Related Traits Consortium (MAGIC) and were downloaded from 
www.magicinvestigators.org.
This work represents independent research funded in part by the U.K. 
National Institute for Health Research (NIHR) Biomedical Research Centre 
at South London and Maudsley NHS Foundation Trust and King’s College 
London. The views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR, or the Department of Health.
Dr. Bulik-Sullivan is an employee and shareholder of Gritstone Oncology. 
Dr. Sullivan has served on a scientific advisory board for Pfizer and an 
advisory committee for Lundbeck and is a grant recipient from Roche. Dr. 
Breen has received grant funding from and served as a consultant to Eli Lilly 
and has received honoraria from Illumina. Dr. Bulik has received grant 
funding from and served as a consultant to Shire and has received royalties 
from Walker Books and Pearson. The other authors report no financial 
relationships with commercial interests. Disclosures for Working Group 
members: Dr. Dikeos has served as a speaker, consultant, or adviser for 
AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Genesis Pharma,
20. Barrett J, Clayton D, Concannon P, et al: Genome-wide association
study and meta-analysis find that over 40 loci affect risk of type
1 diabetes. Nat Genet 2009; 41:703–707
21. Okada Y, Wu D, Trynka G, et al: Genetics of rheumatoid arthritis
contributes to biology and drug discovery. Nature 2014; 506:
376–381
22. Genotype-Tissue Expression Consortium: Human genomics: the
Genotype-TissueExpression (GTEx) pilot analysis:multitissue gene
regulation in humans. Science 2015; 348:648–660
23. Bulik-Sullivan B, Finucane H, Anttila V, et al: An atlas of genetic
correlations across human diseases and traits. Nat Genet 2015; 47:
1236–1241
24. Anttila V, Bulik-Sullivan B, Finucane HK, et al: Analysis of
shared heritability in common disorders of the brain [Internet].
bioRxiv 2016. http://biorxiv.org/content/early/2016/04/16/048991.
article-info
25. Sullivan P, Daly M, O’Donovan M: Genetic architectures of psy-
chiatricdisorders: the emergingpictureand its implications.NatRev
Genet 2012; 13:537–551
26. Visscher PM, Brown MA, McCarthy MI, et al: Five years of GWAS
discovery. Am J Hum Genet 2012; 90:7–24
27. Cederlöf M, Thornton L, Lichtenstein P, et al: Etiological overlap
between obsessive-compulsive disorder and anorexia nervosa: a
longitudinal cohort, family and twin study. World Psychiatry 2015;
14:333–338
28. KayeW,BulikC, ThorntonL, et al: Comorbidity of anxiety disorders
with anorexia and bulimia nervosa. Am J Psychiatry 2004; 161:
2215–2221
29. Cross-DisorderGroupof thePsychiatricGenomicsConsortium, Lee
SH, Ripke S, et al: Genetic relationship between five psychiatric
disorders estimated from genome-wide SNPs. Nat Genet 2013; 45:
984–994
30. Goodman A, Heshmati A, Koupil I: Family history of education
predicts eating disorders across multiple generations among 2 mil-
lion Swedish males and females. PLoS One 2014; 9:e106475
31. Müller M, Geisler C: From the past to future: from energy expen-
diture to energy intake to energy expenditure. Eur J Clin Nutr 2017;
71:358–364
32. Yu YH, Vasselli J, Zhang Y, et al: Metabolic vs hedonic obesity: a
conceptual distinction and its clinical implications. Obes Rev 2015;
16:234–247
33. HinneyA,KesselmeierM, Jall S, et al: Evidence for three genetic loci
involved in both anorexia nervosa risk and variation of body mass
index. Mol Psychiatry 2017; 22:192–201
34. LockeAE,KahaliB,BerndtSI, et al:Genetic studiesofbodymass index
yield new insights for obesity biology. Nature 2015; 518:197–206
35. StelzerG,RosenN,Plaschkes I, et al:TheGeneCards suite: fromgene
data mining to disease genome sequence analyses. Curr Protoc
Bioinformatics 2016; 54:1.30.1–1.30.33
36. Schauder C, Wu X, Saheki Y, et al: Structure of a lipid-bound ex-
tended synaptotagmin indicates a role in lipid transfer. Nature 2014;
510:552–555
37. Föcking M, Lopez LM, English JA, et al: Proteomic and genomic
evidence implicates the postsynaptic density in schizophrenia. Mol
Psychiatry 2015; 20:424–432
38. Sommer I, van Westrhenen R, Begemann M, et al: Efficacy of anti-
inflammatory agents to improve symptoms in patients with schizo-
phrenia: an update. Schizophr Bull 2014; 40:181–191
39. Wang Q, Yang C, Gelernter J, et al: Pervasive pleiotropy between
psychiatric disorders and immune disorders revealed by integrative
analysis of multiple GWAS. Hum Genet 2015; 134:1195–1209
40. Pickrell JK, Berisa T, Liu JZ, et al: Detection and interpretation of
shared genetic influences on 42 human traits. Nat Genet 2016; 48:
709–717
